Biotechnology company Slingshot Therapeutics, part of the Syncona Accelerator, has appointed John Isaac as Chief Scientific Officer and Bobby Soni as Chief Business Officer. 

Isaacs will be responsible for the company’s scientific strategy, progress across the pipeline, and delivery of therapeutic assets. He will also lead the identification, technical assessment and selection of early-stage drug discovery programmes and assets to add to the Slingshot pipeline. 

Soni will oversee all business development activities comprising the company’s outreach, engagement and partnership strategy. This includes the acquisition and in-licensing of drug discovery programmes.  

As part of the board reshuffle, Slingshot’s founding Chief Scientific Officer, Richard Wooster, will transition to a non-executive role as Scientific Advisor and Board Member. 

“We see a valuable opportunity to translate academic innovation into drug candidates that are ready for clinical development,” said Edward Hodgkin, Executive Chair of Slingshot.  

“The combination of Slingshot’s industry-experienced drug development team with Syncona’s investment expertise is creating a powerful platform for the acceleration of academic research. John and Bobby will play an invaluable role in this, and we are delighted to welcome them to the team.” 

 

Bruno Quinney, Content Team, DDW